Featured Research

from universities, journals, and other organizations

New innovation could mean eye injections are a thing of the past

Date:
March 6, 2014
Source:
University College London
Summary:
Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research that could be a breakthrough for the millions worldwide suffering from age-related macular degeneration and other eye disorders.

Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research led by UCL scientists that could be a breakthrough for the millions worldwide suffering from age-related macular degeneration (AMD) and other eye disorders.

1 in 5 people over 75 have AMD with well-known sufferers including actress Dame Judi Dench and author Stephen King. The research findings are significant due to growing patient numbers and an increasing demand for the eye injections that halt the progression of the disease.

The research, demonstrated in animal models and published in nanotechnology journal Small, demonstrates that it is possible to create formulations of tiny nanoparticles loaded with the AMD drug Avastin and deliver significant concentrations to the back of the eye. Lead author Professor Francesca Cordeiro (UCL Institute of Ophthalmology) said: "The development of eye drops that can be safely and effectively used in patients would be a magic bullet -- a huge breakthrough in the treatment of AMD and other debilitating eye disorders.

"The current treatment of injecting drugs into the eye is uncomfortable, detested by patients and often needs repeated monthly injections in hospital for as long as 24 consecutive months. It's impossible to exaggerate the relief patients would feel at not having to experience injections into their eyes."

The NHS is currently overburdened with patients who need repeat eye injections and the numbers are set to rise exponentially over the next ten years. Demand is so high that injections are difficult to administer, time-consuming and very expensive. The treatment also carries a risk of infection and bleeding, increased by the frequency of recurrent injections into the eyes. In the USA, well over one million ocular injections were given in 2010. In the UK, 30,500 injections were estimated to have been given in 2008 -- a 150-fold increase in 10 years.

Effective delivery of drugs to the retina of the eye is considered one of the most challenging areas in drug development in ophthalmology, due to the presence of anatomical barriers. It was previously thought that drugs used to treat AMD such as Avastin and Lucentis have molecules that are simply too large to be effectively transported in an eye drop.

First author Dr Ben Davis (UCL Institute of Ophthalmology) added: "There is significant interest in the development of minimally invasive systems to deliver large drug molecules across biological barriers including the cornea of the eye.

"We have shown in experimental models a formulation system to get substances including Avastin across the barriers in the eye and transport them across the cells of the cornea. In theory, you could customise the technology for different drugs such as Lucentis, commonly used for AMD treatment in the UK, as it is a smaller molecule than Avastin so likely to be delivered effectively via this method.

"All the components we used are safe and well established in the field, meaning we could potentially move quite quickly to get the technology into trials in patients -- but the timescales are dependent on funding." The paper includes functional data showing that the avastin administered stops the blood vessels from leaking and forming new blood vessels, the basis for wet AMD.


Story Source:

The above story is based on materials provided by University College London. Note: Materials may be edited for content and length.


Journal Reference:

  1. Benjamin M. Davis, Eduardo M Normando, Li Guo, Paul O'Shea, Stephen E. Moss, Satyanarayana Somavarapu, M. Francesca Cordeiro. Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5-associated Liposomes. Small, 2014; DOI: 10.1002/smll.201303433

Cite This Page:

University College London. "New innovation could mean eye injections are a thing of the past." ScienceDaily. ScienceDaily, 6 March 2014. <www.sciencedaily.com/releases/2014/03/140306093806.htm>.
University College London. (2014, March 6). New innovation could mean eye injections are a thing of the past. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/03/140306093806.htm
University College London. "New innovation could mean eye injections are a thing of the past." ScienceDaily. www.sciencedaily.com/releases/2014/03/140306093806.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins